Day Two

Thursday September 12 2019

8:20 am Chair’s Opening Remarks

  • Brian Murphy Chief Executive Officer, Emerald Bioscience Inc.

Improving Formulation, Drug Delivery & Preclinical Testing for Greater Clinical Efficacy

8:30 am Improving the Bioavailability of Cannabinoids


• Increase systemic bioavailability of CBN’

• Increase the local availability of CBN’

• Bypassing the first pass (liver metabolism)

9:00 am Unique Methods to Identify Strong Lead Compounds


• Understand lead identification strategy

• Explore different methodologies and their effectiveness in the cannabinoid research field

9:30 am Advancing Personalized Therapies using Cannabinoid APIs


• Discover how Cannabics implement high-throughput screening into R&D process to create more effective therapies

• Look at the preclinical analysis that has been done on current candidates and what results they have yielded

10:00 am Morning Refreshments

Challenges in Clinical Trials & Linking Cannabinoids to their Areas of Therapeutic Potential

11:00 am The Therapeutic Potential of Cannabinoids in Ocular Disease: The EMBI Experience

  • Brian Murphy Chief Executive Officer, Emerald Bioscience Inc.


• Review of endocannabinoid involvement in the eye

• Review of data using a prodrug of THC to manage hypertensive glaucoma

• The potential of cannabinoids to address Asian forms of glaucoma

11:30 am Cannabinoids for Neuropsychiatric Disorders: Focus on Cannabidiol


• Learn how pharmacological challenge with delta-9- tetrahydrocannabinol may be used to model different psychiatric symptoms and understand their neural underpinnings in man

• Learn about King College London’s research showcasing the trajectory of cannabidiol from proof-ofconcept studies to definitive clinical trials- Psychosis exemplar

• Discuss the therapeutic potential for cannabidiol in different neuropsychiatric disorders

12:00 pm Lunch

1:30 pm Comparison of the Anti-Tumor Efficacy of A Whole-Plant Extract Vs. Pure THC in Preclinical Models of HER2-Positive Breast Cancer


• Whole-plant extracts are more effective antitumor tools than pure compounds

• The plant contains hundreds of compounds with potential therapeutic effects

• Explore the cannabinoids that inhibit proliferation of cancer cells in vitro (e.g. THCA, CBDA, etc.) and other non-cannabinoid compounds that activate cannabinoid receptors (e.g. beta-caryophyllene)

• Discuss why most of the constituents of cannabis have not been studied in cancer, even though there is already clinical evidence for other ailments supporting this idea (e.g. effect of marinol vs whole-plant extracts)

2:00 pm Pain & Opioids – How are Cannabinoids Playing a Role in Both Pain Relief & Addiction?


• Analyze recent clinical data to illustrate the potential of cannabinoids in pain relief

• Discuss the challenge of oral cannabinoid formulations for pain relief

• Discuss the potential role cannabinoids could play in curbing addiction

2:30 pm Afternoon Refreshments

3:00 pm Cannabinoids in Dermatology – Sorting Fact From Fiction


• Scientific basis for cannabinoids in skin diseases

• Clinical outcomes

• New research directions

3:30 pm VBX-100: A GI-targeted Prodrug of THC for Inflammatory Bowel Disease

  • Robert Brooke Chief Executive Officer & Co-Founder,
    Director - Scientific Research & Development & Co- Founder, Vitality Biopharma


• Overview of cannabinoids for treatment of inflammatory bowel disease (including pediatric Crohn’s disease and ulcerative colitis) and other GI conditions

• The discovery of cannabosides, a new class of pharmaceutical prodrugs that enable targeting of cannabinoids to the gastrointestinal tract while avoiding psychoactivity

• The production methods for cannabosides, using a novel biocatalysis process enabled by an enzyme derived from the Stevia rebaudiana plant

4:00 pm Targeting the Endocannabinoid System to Develop Medicines to Treat Inflammatory and Fibrotic Diseases

  • Barbara White Chief Medical Officer and Head, Research, Corbus Pharmaceuticals


  • Will discuss opportunities to use CB2 agonists and CB1 inverse agonists as
    medicines to treat inflammatory and fibrotic diseases
  • Will provide specific examples using lenabasum a CB2 agonist and CRB-4001, a
    CB1 inverse agonist

4:30 pm Chair’s Closing Remarks

  • Brian Murphy Chief Executive Officer, Emerald Bioscience Inc.

4:40 pm End of Conference